Here are five things to know:
1. The company’s worldwide sales hit $2.2 billion, a 1.4 percent decrease over the same period last year. The U.S. sales dropped 2.6 percent to $1.3 billion while international sales were up 0.4 percent at $930 million.
2. Hip sales were up 2.9 percent to $360 million, driven by the international sales that jumped nearly 5 percent to $149 million. U.S. sales were up 1.4 percent for the quarter to $211 million.
3. Knee sales were relatively flat, dropping just 0.8 percent to $382 million. U.S. knee sales were down 3 percent to $229 million, partially offset by 2.7 percent gains in international knee sales, which hit $153 million.
4. DePuy Synthes spine and other sales dropped 7.7 percent, led by a 9.2 percent decrease in international sales to $347 million. U.S. spine and other sales also dropped 6.6 percent to $498 million.
5. Trauma sales increased 5 percent, driven by 11 percent growth in international sales to hit $281 million. U.S. trauma sales increased 1 percent to $394 million.
More articles on orthopedic devices:
How 8 big spine companies’ Q2 compared & what to expect in the future
17 key players in the global spine biologics market
Kathie Lenzen joins Xtant Medical as CFO
